Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AM-Pharma Initiates Phase 2 Trial Of Ilofotase Alfa for Kidney Damage
Details : recAP (Ilofotase Alfa), a recombinant alkaline phosphatase, is in Phase 2 trials for cardiac surgery-associated renal damage.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilofotase Alfa
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : FGK Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Ilofotase Alfa for Prevention of Renal Damage After Cardiac Surgery
Details : Ilofotase Alfa is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 13, 2023
Lead Product(s) : Ilofotase Alfa
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : FGK Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, which is investigated for enzyme replacement therapy in adult hypophosphatasia (HPP) patients.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
October 11, 2023
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AM-Pharma Announces Updated Clinical Development Strategy
Details : Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, which is investigated for cardiac surgery-associated renal damage.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
September 26, 2023
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilofotase Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia
Details : Ilofotase Alfa is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hypophosphatasia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 06, 2023
Lead Product(s) : Ilofotase Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that in multiple clinical trials was shown to be stable and highly active.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
October 20, 2022
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study shows ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury in rodents through the activation of adenosine receptors and the metabolism of extracellular adenosine triphosphate (ATP), a pro-inflammatory molecule.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
July 05, 2022
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that in multiple clinical trials was shown to be stable and highly active.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
April 25, 2022
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that was shown in multiple clinical trials to be stable and highly active.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : Inapplicable
March 07, 2022
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Kyowa Kirin
Deal Size : $290.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, AM-Pharma is entitled to tiered double-digit royalties on sales and a drug supply fee. Kyowa Kirin will gain the exclusive right to develop and commercialize ilofotase alfa in Japan.
Product Name : recAP
Product Type : Enzyme
Upfront Cash : $23.6 million
September 08, 2021
Lead Product(s) : Ilofotase Alpha
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Kyowa Kirin
Deal Size : $290.0 million
Deal Type : Licensing Agreement